Bioxyne Secures Initial Purchase Orders for Psychedelic Drug; Shares Rise 7%

MT Newswires Live

5 hours ago

Bioxyne (ASX:BXN) secured initial purchase orders for the supply of psilocybin capsules, or BLSPSIL25, through its wholly-owned unit Breathe Life Sciences, according to a Wednesday Australian bourse filing.

The capsules are intended for investigational use in treatment-resistant depression and exploratory research into other mental health conditions in Australia, including anxiety disorders, substance use disorders, and post-traumatic stress disorder.

These initial orders involve the supply of 250 doses of BLSPSIL25 to authorized prescribers in Queensland and Western Australia, supporting treatment for around 60 patients over the next 12 months.

Bioxyne's shares rose nearly 7% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610606323"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610606323\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610606323?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610606323","market":"us","top_or_hot":-1,"title":"Bioxyne Secures Initial Purchase Orders for Psychedelic Drug; Shares Rise 7%","media":"MT Newswires Live","content":"<html><body><p> Bioxyne (ASX:BXN) secured initial purchase orders for the supply of psilocybin capsules, or BLSPSIL25, through its wholly-owned unit Breathe Life Sciences, according to a Wednesday Australian bourse filing.</p><p>The capsules are intended for investigational use in treatment-resistant depression and exploratory research into other mental health conditions in Australia, including anxiety disorders, substance use disorders, and post-traumatic stress disorder.</p><p>These initial orders involve the supply of 250 doses of BLSPSIL25 to authorized prescribers in Queensland and <a href=\"https://laohu8.com/S/WER.AU\">Western Australia</a>, supporting treatment for around 60 patients over the next 12 months.</p><p>Bioxyne's shares rose nearly 7% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bioxyne Secures Initial Purchase Orders for Psychedelic Drug; Shares Rise 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioxyne Secures Initial Purchase Orders for Psychedelic Drug; Shares Rise 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-11 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Bioxyne (ASX:BXN) secured initial purchase orders for the supply of psilocybin capsules, or BLSPSIL25, through its wholly-owned unit Breathe Life Sciences, according to a Wednesday Australian bourse filing.</p><p>The capsules are intended for investigational use in treatment-resistant depression and exploratory research into other mental health conditions in Australia, including anxiety disorders, substance use disorders, and post-traumatic stress disorder.</p><p>These initial orders involve the supply of 250 doses of BLSPSIL25 to authorized prescribers in Queensland and <a href=\"https://laohu8.com/S/WER.AU\">Western Australia</a>, supporting treatment for around 60 patients over the next 12 months.</p><p>Bioxyne's shares rose nearly 7% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BXN.AU","symbol_name":"BIOXYNE LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2610606323","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610606323","pubTimestamp":1770775250,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bioxyne  secured initial purchase orders for the supply of psilocybin capsules, or BLSPSIL25, through its wholly-owned unit Breathe Life Sciences, according to a Wednesday Australian bourse filing.The capsules are intended for investigational use in treatment-resistant depression and exploratory research into other mental health conditions in Australia, including anxiety disorders, substance use disorders, and post-traumatic stress disorder.These initial orders involve the supply of 250 doses of BLSPSIL25 to authorized prescribers in Queensland and Western Australia, supporting treatment for around 60 patients over the next 12 months.Bioxyne's shares rose nearly 7% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BXN.AU":"BIOXYNE LTD","XKO.AU":"标普/澳交所 300指数","XAO.AU":"标普/澳交所 普通股指数","BK7508":"医药生物股","BK7111":"个人用品","XJO.AU":"标普/澳交所 200指数"},"translate_title":"Bioxyne获得迷幻药的初始采购订单；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BXN.AU":1,"XKO.AU":0.64,"XJO.AU":0.64,"XAO.AU":0.64},"content_text":"Bioxyne (ASX:BXN) secured initial purchase orders for the supply of psilocybin capsules, or BLSPSIL25, through its wholly-owned unit Breathe Life Sciences, according to a Wednesday Australian bourse filing.The capsules are intended for investigational use in treatment-resistant depression and exploratory research into other mental health conditions in Australia, including anxiety disorders, substance use disorders, and post-traumatic stress disorder.These initial orders involve the supply of 250 doses of BLSPSIL25 to authorized prescribers in Queensland and Western Australia, supporting treatment for around 60 patients over the next 12 months.Bioxyne's shares rose nearly 7% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}